Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505).
暂无分享,去创建一个
W. Curran | R. Jeraj | J. Bradley | D. Gerber | B. Movsas | C. Langer | Chen Hu | J. Urbanic | B. Lu | I-Fen Chang
[1] D. Gerber,et al. Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options. , 2016, JAMA oncology.
[2] M. Socinski,et al. NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC , 2016 .
[3] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[4] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[5] J. Ahn,et al. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] T. Aparicio,et al. PD-1 blockade in tumors with mismatch-repair deficiency , 2015 .
[7] David C. Smith,et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[9] M. Kelley,et al. Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] W. Curran,et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.
[11] M. Galsky,et al. Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[12] Y. Shim,et al. PD-L1 expression and survival in patients with non-small cell lung cancer (NSCLC) in Korea. , 2014 .
[13] R. Weichselbaum,et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.
[14] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[15] P. Iyengar,et al. Locally Advanced Lung Cancer: An Optimal Setting for Vaccines and Other Immunotherapies , 2013, Cancer journal.
[16] Shixiu Wu,et al. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. , 2012, Lung cancer.
[17] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[18] Alison P. Klein,et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.
[19] Jedd D. Wolchok,et al. Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.
[20] Vincenzo Valentini,et al. Lung abnormalities at multimodality imaging after radiation therapy for non-small cell lung cancer. , 2011, Radiographics.
[21] Israel Lowy,et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[23] R. Weichselbaum,et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.
[24] J. Crowley,et al. The revised TNM staging system for lung cancer. , 2009, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.
[25] Cynthia S. Johnson,et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Crowley,et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Talmadge,et al. Inflammatory cell infiltration of tumors: Jekyll or Hyde , 2007, Cancer and Metastasis Reviews.
[28] Walter J Curran,et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] N. Kawashima,et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. , 2004, International journal of radiation oncology, biology, physics.
[30] S. McDonald,et al. Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. , 1995, International journal of radiation oncology, biology, physics.
[31] M. Socinski,et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.
[32] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[33] A. Uchida,et al. Effects of X-ray irradiation on natural killer (NK) cell system. I. Elevation of sensitivity of tumor cells and lytic function of NK cells. , 1989, Immunopharmacology and immunotoxicology.